Botanical expertise preventing metabolic disease

Therapeutic areas

Prediabetes, dyslipidemia, arterial hypertension, metabolic liver diseases: at Valbiotis, our research targets the main metabolic and cardiovascular risk factors.

Read more
Therapeutic areas

Pipeline

Four plant-based active substances in clinical development to reduce the risk of metabolic and cardiovascular diseases.

Read more
Pipeline

Investors

For news, financial documents and the shareholders’ space.

Read more
Investors

Latest News

Finance
06/26/2025

Valbiotis announces the success of its €6.9 million rights issue

Download
Finance
06/06/2025

Launch of a capital increase

Download
Corporate
05/22/2025

Valbiotis to launch ValbiotisPRO® Cardio-circulation on 2 June

Download
Corporate
05/06/2025

Strong Start to the Year in Line

Download